1
|
Nationwide survey of hospital antibiotic stewardship programs in France. Med Mal Infect 2019; 50:414-422. [PMID: 31575446 DOI: 10.1016/j.medmal.2019.09.007] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2018] [Revised: 11/06/2018] [Accepted: 09/03/2019] [Indexed: 12/26/2022]
Abstract
OBJECTIVE We aimed to evaluate the current state of antibiotic stewardship (ABS) in French public and private acute care hospitals. METHODS We conducted a cross-sectional online questionnaire survey. The selection of participating hospitals was performed through a stratified random sampling procedure among all French public and private hospitals with acute care beds. RESULTS 97/215 (45%) hospitals participated. A formal ABS program was implemented in 84% (80/95) of hospitals. A person officially in charge of this program (i.e., ABS program leader) was present in almost all participating hospitals (99%, 95/96) and s/he coordinated a multidisciplinary ABS team in 42% (40/96) of cases. The median time spent on ABS activities was 1.7, 1.6, and 0.8hours/week/100 acute care beds for infectious disease (ID) specialists, pharmacists, and microbiologists respectively; 27% (7/26) of ID specialists/other clinicians, 58% (15/26) of pharmacists, and 80% (16/20) of microbiologists received no salary support for the stewardship activities conducted as part of the team. Local guidelines (94%, 88/94), electronic medical records (85%, 80/94), and an antibiotic restriction policy (92%, 82/89) were implemented in almost all hospitals. Reports on antibiotic consumption and local resistance rates were available in 100% (91/91) and 84% (76/91) of hospitals, respectively. CONCLUSION Despite the existence of national requirements, hospital ABS programs are not fully implemented in France, mainly because of inadequate institutional support and funding.
Collapse
|
2
|
Abedon ST. Use of phage therapy to treat long-standing, persistent, or chronic bacterial infections. Adv Drug Deliv Rev 2019; 145:18-39. [PMID: 31708017 DOI: 10.1016/j.addr.2018.06.018] [Citation(s) in RCA: 47] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2018] [Revised: 03/10/2018] [Accepted: 06/23/2018] [Indexed: 01/01/2023]
Abstract
Viruses of bacteria - known as bacteriophages or phages - have been used clinically as antibacterial agents for nearly 100 years. Often this phage therapy is of long-standing, persistent, or chronic bacterial infections, and this can be particularly so given prior but insufficiently effective infection treatment using standard antibiotics. Such infections, in turn, often have a biofilm component. Phages in modern medicine thus are envisaged to serve especially as anti-biofilm/anti-persistent infection agents. Here I review the English-language literature concerning in vivo experimental and clinical phage treatment of longer-lived bacterial infections. Overall, published data appears to be supportive of a relatively high potential for phages to cure infections which are long standing and which otherwise have resisted treatment with antibieiotics.
Collapse
|
3
|
Ogunleye OO, Fadare JO, Yinka-Ogunleye AF, Anand Paramadhas BD, Godman B. Determinants of antibiotic prescribing among doctors in a Nigerian urban tertiary hospital. Hosp Pract (1995) 2019; 47:53-58. [PMID: 29757036 DOI: 10.1080/21548331.2018.1475997] [Citation(s) in RCA: 39] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2018] [Accepted: 05/09/2018] [Indexed: 06/08/2023]
Abstract
OBJECTIVES The problem of antimicrobial resistance (AMR) has assumed pandemic dimensions especially among low-and middle-income countries such as Nigeria. Irrational use of currently available antimicrobial agents is a major contributory factor. There remains a paucity of documented information on the determinants of antibiotic prescribing among physicians in Nigeria to guide future strategies to reduce AMR. This study therefore aimed to investigate the patterns and determinants of antibiotic prescribing among doctors in a tertiary hospital in Nigeria as the first step to improve future antibiotic use in hospitals. METHODS A cross-sectional survey of the determinants of antibiotic prescribing among doctors in the Lagos State University Teaching Hospital, Ikeja, was performed using a structured questionnaire. Information was obtained about the doctors and the factors determining their prescription of antibiotics. The results were summarized using descriptive statistics with Statistical Package for Social Science. RESULTS Ninety-eight respondents were studied with a mean age of 36.24(9.01) years, a mean duration of practice of 10.68(9.25) years, and mainly males (64.3%). Ninety-seven percent prescribe antibiotics frequently, mostly based on clinical judgment and experience with rare laboratory supports. Factors of cost, drug availability, and information from pharmaceutical representatives influenced antibiotic prescribing. There were indications of nonexistence or nonfunctional institutional policies and guidelines regarding antimicrobial therapies. CONCLUSION There is an urgent need to institute evidence-based institutional policies and guidelines for improving antimicrobial use among hospitals in Nigeria. This is already being followed up.
Collapse
Affiliation(s)
- Olayinka O Ogunleye
- a Department of Pharmacology, Therapeutics and Toxicology , Lagos State University College of Medicine , Ikeja , Nigeria
- b Department of Medicine , Lagos State University Teaching Hospital , Ikeja , Nigeria
| | - Joseph O Fadare
- c Department of Pharmacology and Therapeutics, College of Medicine , Ekiti State University , Ado-Ekiti , Nigeria
| | | | | | - Brian Godman
- f Division of Clinical Pharmacology, Department of Laboratory Medicine , Karolinska Institute, Karolinska University Hospital , Stockholm , Sweden
- g Strathclyde Institute of Pharmacy and Biomedical Sciences , University of Strathclyde , Glasgow , UK
| |
Collapse
|
4
|
Antão EM, Vincze S, Hanke R, Klimmek L, Suchecka K, Lübke-Becker A, Wieler LH. Antibiotic resistance, the 3As and the road ahead. Gut Pathog 2018; 10:52. [PMID: 30598701 PMCID: PMC6303944 DOI: 10.1186/s13099-018-0280-7] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/06/2018] [Accepted: 12/18/2018] [Indexed: 12/11/2022] Open
Abstract
Antibiotic resistance is by far one of the most important health threats of our time. Only a global concerted effort of several disciplines based on the One-Health concept will help in slowing down this process and potentially mitigate the ruin of healthcare we have come to enjoy. In this review, we attempt to summarize the most basic and important topics that serve as good information tools to create Awareness. The Availability of antibiotics or the lack thereof is another significant factor that must be given thought, and finally because antibiotic resistance is a problem that will not go away, it is important to have Alternatives. Together, we have the 3As, essential concepts, in dealing with this growing and complex problem.
Collapse
Affiliation(s)
- Esther-Maria Antão
- 1Centre for Infection Medicine, Institute of Microbiology and Epizootics, Freie University Berlin, Robert-von-Ostertag Str. 7-13, 14163 Berlin, Germany.,2Robert-Koch-Institute, Nordufer 20, 13353 Berlin, Germany
| | - Szilvia Vincze
- 1Centre for Infection Medicine, Institute of Microbiology and Epizootics, Freie University Berlin, Robert-von-Ostertag Str. 7-13, 14163 Berlin, Germany.,4Department of Biological Safety, German Federal Institute for Risk Assessment, Max-Dohrn-Str. 8-10, 10589 Berlin, Germany
| | - Regina Hanke
- Lindgrün GmbH, Cuxhavener Str. 12, 10557 Berlin, Germany
| | - Lukas Klimmek
- Lindgrün GmbH, Cuxhavener Str. 12, 10557 Berlin, Germany
| | | | - Antina Lübke-Becker
- 1Centre for Infection Medicine, Institute of Microbiology and Epizootics, Freie University Berlin, Robert-von-Ostertag Str. 7-13, 14163 Berlin, Germany
| | | |
Collapse
|
5
|
Haque M, McKimm J, Godman B, Abu Bakar M, Sartelli M. Initiatives to reduce postoperative surgical site infections of the head and neck cancer surgery with a special emphasis on developing countries. Expert Rev Anticancer Ther 2018; 19:81-92. [DOI: 10.1080/14737140.2019.1544497] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Affiliation(s)
- Mainul Haque
- Faculty of Medicine and Defence Health, Universiti Pertahanan Nasional Malaysia (National Defence University of Malaysia), Kuala Lumpur, Malaysia
| | - Judy McKimm
- Swansea University School of Medicine, Grove Building, Swansea University, Swansea, Wales, UK
| | - Brian Godman
- Strathclyde Institute of Pharmacy and Biomedical Sciences, Strathclyde University, Glasgow, United Kingdom
- Division of Clinical Pharmacology, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
- Department of Public Health Pharmacy and Management, School of Pharmacy, Sasako Makgatho Health Sciences University, Garankuwa, South Africa
| | - Muhamad Abu Bakar
- Faculty of Medicine and Defence Health, Universiti Pertahanan Nasional Malaysia (National Defence University of Malaysia), Kuala Lumpur, Malaysia
| | - Massimo Sartelli
- Department of Surgery, Macerata Hospital, Via Santa Lucia 2, 62100 Macerata, Italy
| |
Collapse
|
6
|
Périllaud C, Pilmis B, Diep J, Péan de Ponfilly G, Vidal B, Couzigou C, Mizrahi A, Lourtet-Hascoët J, Le Monnier A, Nguyen Van JC. Prospective evaluation of rapid antimicrobial susceptibility testing by disk diffusion on Mueller-Hinton rapid-SIR directly on blood cultures. Diagn Microbiol Infect Dis 2018; 93:14-21. [PMID: 30149988 DOI: 10.1016/j.diagmicrobio.2018.07.016] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2018] [Revised: 07/24/2018] [Accepted: 07/25/2018] [Indexed: 11/15/2022]
Abstract
BACKGROUND With the worldwide spread of antibiotic resistance, delivering antibiotic susceptibility test (AST) results in a timely manner represents a major challenge. In cases of sepsis, rapid AST may facilitate early optimization of empiric antibiotic therapy. Disc diffusion is a well-standardized AST method, however 16 to 24 h are required to achieve an overall AST profile according to antimicrobial societies. METHODS In this prospective pilot study, we evaluated the performance of Mueller-Hinton-Rapid-SIR (MHR-SIR) agar after 6-8 h of incubation in comparison with standard MH agar after 16 h of incubation directly on positive blood cultures caused by Enterobacteriaceae and Staphylococcus aureus from routine clinical microbiology. A total of 133 positive blood samples including 110 Enterobacteriaceae (83%) and 23 Staphylococcus aureus (17%) were tested in parallel by two direct AST methods, each using EUCAST breakpoints. For each combination bacterium and antibiotic, we compared the categorical agreement and the correlation between the diameters obtained by MHR-SIR and by standard MH. RESULTS Our results showed 97.7% categorical agreement for Enterobacteriaceae, with 1.4% minor errors, 0.4% major errors and 0.5% very major errors. For S. aureus, we observed 97.8% categorical agreement, 1.9% minor errors, 0.3% major errors and no very major errors. CONCLUSION Our results showed excellent categorical agreement and correlations between diameters for MHR-SIR and standard MH methods. MHRSIR can predict the result of overall AST profile within 6-8 h with reliable results. AST is obtained on the same day the blood culture becomes positive, with a very moderate cost.
Collapse
Affiliation(s)
- Claire Périllaud
- Service de Microbiologie Clinique, Groupe Hospitalier Paris Saint-Joseph, Paris, France
| | - Benoît Pilmis
- Unité Mobile de Microbiologie Clinique, Groupe Hospitalier Paris Saint-Joseph, Paris, France
| | - Julien Diep
- Unité Mobile de Microbiologie Clinique, Groupe Hospitalier Paris Saint-Joseph, Paris, France
| | | | - Barbara Vidal
- Unité Mobile de Microbiologie Clinique, Groupe Hospitalier Paris Saint-Joseph, Paris, France
| | - Carine Couzigou
- Unité Mobile de Microbiologie Clinique, Groupe Hospitalier Paris Saint-Joseph, Paris, France
| | - Assaf Mizrahi
- Service de Microbiologie Clinique, Groupe Hospitalier Paris Saint-Joseph, Paris, France
| | - Julie Lourtet-Hascoët
- Service de Microbiologie Clinique, Groupe Hospitalier Paris Saint-Joseph, Paris, France
| | - Alban Le Monnier
- Service de Microbiologie Clinique, Groupe Hospitalier Paris Saint-Joseph, Paris, France
| | - Jean-Claude Nguyen Van
- Service de Microbiologie Clinique, Groupe Hospitalier Paris Saint-Joseph, Paris, France.
| |
Collapse
|
7
|
Abat C, Fournier PE, Jimeno MT, Rolain JM, Raoult D. Extremely and pandrug-resistant bacteria extra-deaths: myth or reality? Eur J Clin Microbiol Infect Dis 2018; 37:1687-1697. [PMID: 29956024 DOI: 10.1007/s10096-018-3300-0] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2017] [Accepted: 06/06/2018] [Indexed: 12/16/2022]
Abstract
In 2009, the European Centre for Disease Prevention and Control (ECDC) estimated that multidrug-resistant (MDR) bacterial infections were responsible for 25,000 extra-deaths per year. In 2015, another report estimated that 12,500 extra-deaths were attributable to MDR bacteria every year in France. Recently, the United Nations claimed that resistance to antimicrobials was a global scourge, forecasting 10 million deaths in 2050. Surprisingly, our antibiotic resistance surveillance system in Marseille, France, did not allowed us to observe similar trends. We herein compared our data on extremely drug-resistant (XDR)/pandrug-resistant (PDR) patient extra-deaths to evaluations and predictions from these reports. First, we retrospectively collect and analyze antibiotic resistance data produced by our settings between November 2009 and March 2015 to look for 30-day deaths attributable to XDR/PDR strains belonging to 11 bacterial species/genus. In parallel, we performed a PubMed literature search to look for articles published prior to July 2016 and describing human deaths due to PDR strains. Overall, 35,723 patients were infected by at least one bacterial species/genus of interest and 85 by XDR/PDR strains. Of these patients, only one death was attributable to a XDR bacterial infection in a patient with strong comorbidities and two consecutive septic shocks. Our literature review shows that only four articles described human deaths due to PDR bacteria. All together, these data allowed us to conclude that there is a large discrepancy between the real count of deaths attributable to XDR/PDR bacteria and alarmist predictions.
Collapse
Affiliation(s)
- Cédric Abat
- IRD, MEPHI, AP-HM, IHU-Méditerranée-Infection, Aix-Marseille University, Marseille, France
| | - Pierre-Edouard Fournier
- IRD, VITROME, AP-HM, SSA, IHU-Méditerranée-Infection, Aix-Marseille University, Marseille, France
| | - Marie-Thérèse Jimeno
- IRD, VITROME, AP-HM, SSA, IHU-Méditerranée-Infection, Aix-Marseille University, Marseille, France
| | - Jean-Marc Rolain
- IRD, MEPHI, AP-HM, IHU-Méditerranée-Infection, Aix-Marseille University, Marseille, France.
- URMITE, UMR CNRS 7278, IRD 198, INSERM U1095, Faculté de Médecine, 27 boulevard Jean Moulin, 13385, Marseille CEDEX 5, France.
| | - Didier Raoult
- IRD, MEPHI, AP-HM, IHU-Méditerranée-Infection, Aix-Marseille University, Marseille, France.
- URMITE, UMR CNRS 7278, IRD 198, INSERM U1095, Faculté de Médecine, 27 boulevard Jean Moulin, 13385, Marseille CEDEX 5, France.
| |
Collapse
|
8
|
Goycochea-Valdivia WA, Moreno-Ramos F, Paño-Pardo JR, Aracil-Santos FJ, Baquero-Artigao F, del Rosal-Rabes T, Mellado-Peña MJ, Escosa-García L. Identifying priorities to improve paediatric in-hospital antimicrobial use by cross-sectional evaluation of prevalence and appropriateness of prescription. Enferm Infecc Microbiol Clin 2017; 35:556-562. [DOI: 10.1016/j.eimc.2017.01.011] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2016] [Revised: 01/24/2017] [Accepted: 01/27/2017] [Indexed: 11/27/2022]
|
9
|
Ecology of Anti-Biofilm Agents I: Antibiotics versus Bacteriophages. Pharmaceuticals (Basel) 2015; 8:525-58. [PMID: 26371010 PMCID: PMC4588182 DOI: 10.3390/ph8030525] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2015] [Revised: 08/30/2015] [Accepted: 09/01/2015] [Indexed: 12/11/2022] Open
Abstract
Bacteriophages, the viruses that infect bacteria, have for decades been successfully used to combat antibiotic-resistant, chronic bacterial infections, many of which are likely biofilm associated. Antibiotics as anti-biofilm agents can, by contrast, be inefficacious against even genetically sensitive targets. Such deficiencies in usefulness may result from antibiotics, as naturally occurring compounds, not serving their producers, in nature, as stand-alone disruptors of mature biofilms. Anti-biofilm effectiveness by phages, by contrast, may result from a combination of inherent abilities to concentrate lytic antibacterial activity intracellularly via bacterial infection and extracellularly via localized population growth. Considered here is the anti-biofilm activity of microorganisms, with a case presented for why, ecologically, bacteriophages can be more efficacious than traditional antibiotics as medically or environmentally applied biofilm-disrupting agents. Four criteria, it can be argued, generally must be met, in combination, for microorganisms to eradicate biofilms: (1) Furnishing of sufficiently effective antibacterial factors, (2) intimate interaction with biofilm bacteria over extended periods, (3) associated ability to concentrate antibacterial factors in or around targets, and, ultimately, (4) a means of physically disrupting or displacing target bacteria. In nature, lytic predators of bacteria likely can meet these criteria whereas antibiotic production, in and of itself, largely may not.
Collapse
|
10
|
Walewski V, Podglajen I, Lefeuvre P, Dutasta F, Neuschwander A, Tilouche L, Carbonnelle E, Ferroni A. Early detection with the β-LACTA™ test of extended-spectrum β-lactamase-producing Enterobacteriaceae in blood cultures. Diagn Microbiol Infect Dis 2015; 83:216-8. [PMID: 26256418 DOI: 10.1016/j.diagmicrobio.2015.07.005] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2015] [Revised: 07/09/2015] [Accepted: 07/10/2015] [Indexed: 11/18/2022]
Abstract
Effective antibiotic therapy is crucial for the outcome of septic patients and requires early diagnosis of β-lactam resistance in cases of Gram-negative bacteremia. Here, we report high sensitivity of the β-LACTA™ test in rapid detection of extended-spectrum β-lactamase-producing Enterobacteriaceae in blood cultures positive for Gram-negative bacilli.
Collapse
Affiliation(s)
- V Walewski
- Microbiology, AP-HP, Hôpital Européen Georges Pompidou, Paris, France.
| | - I Podglajen
- Microbiology, AP-HP, Hôpital Européen Georges Pompidou, Paris, France; Université Paris Descartes, Paris, France
| | - P Lefeuvre
- Microbiology, AP-HP, Hôpital Necker-Enfants Malades, Paris, France
| | - F Dutasta
- Microbiology, AP-HP, Hôpital Européen Georges Pompidou, Paris, France
| | - A Neuschwander
- Microbiology, AP-HP, Hôpital Européen Georges Pompidou, Paris, France
| | - L Tilouche
- Microbiology, AP-HP, Hôpital Européen Georges Pompidou, Paris, France
| | - E Carbonnelle
- Microbiology, AP-HP, Hôpital Européen Georges Pompidou, Paris, France; Université Paris Descartes, Paris, France
| | - A Ferroni
- Université Paris Descartes, Paris, France; Microbiology, AP-HP, Hôpital Necker-Enfants Malades, Paris, France
| |
Collapse
|